1-(甲基磺酰基)-L-脯氨酸叔丁酯 | 360045-23-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1-(甲基磺酰基)-L-脯氨酸叔丁酯
• 英文名称: 1-(methylsulfonyl)-L-proline tert-butyl ester
• 英文别名: tert-butyl (methylsulfonyl)-L-prolinate；tert-butyl (S)-1-methanesulfonyl-pyrrolidine-2-carboxylate；tert-butyl (2S)-1-methylsulfonylpyrrolidine-2-carboxylate
• CAS: 360045-23-4
• 化学式: C₁₀H₁₉NO₄S
• 分子量: 249.331
• InChiKey: MNBJAMRYQJWIRR-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(甲基磺酰基)-L-脯氨酸叔丁酯 在 盐酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 生成 1-(甲基磺酰基)-l-脯氨酸
  参考文献：
  名称：

  [EN] (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF
  [FR] COMPOSÉS (4-HYDROXYPYRROLIDIN-2-YL)-HÉTÉROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  本公开涉及公式（I）的双功能化合物，可用作靶向泛素化的调节剂。具体而言，本公开涉及包含一端为VHL配体基团的化合物，该基团结合到VHL E3泛素连接酶，另一端为结合靶蛋白的基团，从而实现靶蛋白/多肽的降解。还公开了公式（III）的VHL配体。

  公开号：

  WO2019084026A1
• 作为产物：
  描述：

  L-脯氨酸叔丁酯 、 甲基磺酸酐 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以69.3%的产率得到1-(甲基磺酰基)-L-脯氨酸叔丁酯
  参考文献：
  名称：

  [EN] (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF
  [FR] COMPOSÉS (4-HYDROXYPYRROLIDIN-2-YL)-HÉTÉROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  本公开涉及公式（I）的双功能化合物，可用作靶向泛素化的调节剂。具体而言，本公开涉及包含一端为VHL配体基团的化合物，该基团结合到VHL E3泛素连接酶，另一端为结合靶蛋白的基团，从而实现靶蛋白/多肽的降解。还公开了公式（III）的VHL配体。

  公开号：

  WO2019084026A1

文献信息

• Alpha4beta1 and alpha4beta7 integrin inhibitors
  申请人：——

  公开号：US20020091142A1

  公开（公告）日：2002-07-11

  Compounds of the formula I 1 as defined and their pharmaceutically acceptable salts are inhibitors of &agr; 4 &bgr; 1 and/or &agr; 4 &bgr; 7 integrins, and are useful in inhibiting cell adhesion and in the therapeutic or prophylactic treatment of transplant rejection and inflammatory and autoimmune diseases.

  公式I1所定义的化合物及其药用盐是α4β1和/或α4β7整合素的抑制剂，并且在抑制细胞粘附以及治疗或预防移植排斥和炎症性和自身免疫疾病方面是有用的。
• (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
  申请人：Genentech, Inc.

  公开号：US11242344B2

  公开（公告）日：2022-02-08

  The present disclosure relates to bifunctional compounds, which can be used as modulators of targeted ubiquitination. In particular, the present disclosure is directed to compounds which contain on one end a VHL ligand moiety, which binds to the VHL E3 ubiquitin ligase, and on the other end a moiety that binds a target protein such that degradation of the target protein/polypeptide is effectuated. Also disclosed are VHL ligands.

  本公开涉及可用作靶向泛素化调节剂的双功能化合物。特别是，本公开涉及的化合物一端含有与 VHL E3 泛素连接酶结合的 VHL 配体分子，另一端含有与靶蛋白结合的分子，从而实现靶蛋白/多肽的降解。还公开了 VHL 配体。
• (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Genentech, Inc.

  公开号：US20210309660A1

  公开（公告）日：2021-10-07

  The present disclosure relates to bifunctional compounds, which can be used as modulators of targeted ubiquitination. In particular, the present disclosure is directed to compounds which contain on one end a VHL ligand moiety, which binds to the VHL E3 ubiquitin ligase, and on the other end a moiety that binds a target protein such that degradation of the target protein/polypeptide is effectuated. Also disclosed are VHL ligands.
• Potent, Small-Molecule Inhibitors of Human Mast Cell Tryptase. Antiasthmatic Action of a Dipeptide-Based Transition-State Analogue Containing a Benzothiazole Ketone
  作者：Michael J. Costanzo、Stephen C. Yabut、Harold R. Almond,、Patricia Andrade-Gordon、Thomas W. Corcoran、Lawrence de Garavilla、Jack A. Kauffman、William M. Abraham、Rosario Recacha、Debashish Chattopadhyay、Bruce E. Maryanoff

  DOI：10.1021/jm030050p

  日期：2003.8.1

  Inhibitors of human mast cell tryptase (EC 3.4.21.59) have therapeutic potential for treating allergic or inflammatory disorders. We have investigated transition-state mimetics possessing a heterocycle-activated ketone group and identified in particular benzothiazole ketone (2S)-6 (RWJ-56423) as a potent, reversible, low-molecular-weight tryptase inhibitor with a K-i value of 10 nM. A single-crystal X-ray analysis of the sulfate salt of (2S)-6 confirmed the stereochemistry. Analogues 12 and 15-17 are also potent tryptase inhibitors. Although RWJ-56423 potently inhibits trypsin (K-i = 8.1 nM), it is selective vs other serine proteases, such as kallikrein, plasmin, and thrombin. We obtained an X-ray structure of (2S)-6 complexed with bovine trypsin (1.9-Angstrom resolution), which depicts inter alia a hemiketal involving Ser-189, and hydrogen bonds with His-57 and Gln-192. Aerosol administration of 6 (2R,2S; RWJ-58643) to allergic sheep effectively antagonized antigen-induced asthmatic responses, with 70-75% blockade of the early response and complete ablation of the late response and airway hyperresponsiveness.
• [EN] (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS (4-HYDROXYPYRROLIDIN-2-YL)-HÉTÉROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：GENENTECH INC

  公开号：WO2019084026A1

  公开（公告）日：2019-05-02

  The present disclosure relates to bifunctional compounds of formula (I), which can be used as modulators of targeted ubiquitination. In particular, the present disclosure is directed to compounds which contain on one end a VHL ligand moiety, which binds to the VHL E3 ubiquitin ligase, and on the other end a moiety that binds a target protein such that degradation of the target protein/polypeptide is effectuated. Also disclosed are VHL ligands of formula (III).

  本公开涉及公式（I）的双功能化合物，可用作靶向泛素化的调节剂。具体而言，本公开涉及包含一端为VHL配体基团的化合物，该基团结合到VHL E3泛素连接酶，另一端为结合靶蛋白的基团，从而实现靶蛋白/多肽的降解。还公开了公式（III）的VHL配体。